Biomedtech Portfolio

Evexta Bio

Developing Next Generation Precision Cancer Therapies

Evexta's Website

Evexta Bio, founded by Truffle Capital in 2013, is a Biotech company developing next generation breast cancer treatments. Their lead compound, Rupitasertib, is a dual inhibitor within the AKT1/AKT3 cascade, designed to slow tumor proliferation in several types of cancer.

OTHER COMPANIES

Spikimm

SpikImm develops long-acting mAbs to prevent viral infections in imunocompromized patients, in pa...

PK Med

Locally administered therapeutic products to address inflammatory joint diseases and tissue regen...

Skinosive

Bio-adhesive UV filters for long lasting and broad-spectrum sun protection

Caranx Medical

Autonomous robot improving efficiency and safety in Transcatheter Aortic Valve Replacement (TAVI...

BariaTek

Minimally invasive, atraumatic, reversible and endoscopically delivered medical device to treat o...

Artedrone

Autonomous robotic solution to increase the accessibility of mechanical thrombectomy during acute...

Carbios

Biotechnology powering plastic and textile circularity

Affluent Medical

Minimally invasive, biomimetic and adjustable solutions for mitral regurgitation and urinary inco...

Abivax

Regulating the immune response through microRNA

Holistick Medical

Patent Foramen Ovale (PFO) treatment through next generation medical devices